吸入氧化输送系统用于肺动脉高血压治疗
Yoogyeong Oh1, Kyungtae Park1, Sungwon Jung1
1School of Chemical & Biomolecular Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Small (Weinheim an der Bergstrasse, Germany)
|December 6, 2023
概括
新的可吸入的氧化 (NO) 微球为肺动脉高血压 (PAH) 提供了有前途的治疗方法. 这些开放的多孔NO吸入器 (OPNI) 有效地将NO深入肺部,为PAH患者提供血管扩张和抗炎功效.
科学领域:
- 生物材料科学 生物材料科学
- 肺部医学 肺部医学
- 纳米技术 纳米技术
背景情况:
- 肺动脉高血压 (PAH) 是一种严重的疾病,其特征是肺动脉高压.
- 氧化 (NO) 是血管扩张剂,但吸入的NO由于传递挑战和毒性而存在临床限制.
- 需要新的输送系统来安全有效地为PAH治疗提供NO.
研究的目的:
- 开发可吸入的释放氧化 (NO) 的微球 (NO吸入器) 用于肺动脉高血压 (PAH) 治疗.
- 研究具有受控多孔结构的NO吸入器的制造和特性.
- 评估开放多孔NO吸入器 (OPNI) 对深肺输送和治疗效果的疗效.
主要方法:
- 制造可吸入的释放NO的微球,具有明显的多孔结构.
- 通过调节水分子迁移来控制毛孔形成.
- 通过雾化进行NO输送的评估以及血管扩张和抗炎作用的评估.
主要成果:
- 制备了两种类型的NO吸入器,孔隙形成取决于NO的捐赠分子量.
- 开放多孔NO吸入器 (OPNI) 通过雾化证明了有效的深肺输送.
- OPNI表现出持续的NO释放,导致血管扩张和抗炎作用.
结论:
- 开放多孔NO吸入器 (OPNI) 是肺动脉高血压 (PAH) 治疗的可行工具.
- 这项研究强调了高度多孔结构在有效的NO输送到肺中的潜力.
- 在PAH中,OPNI为基于NO的治疗提供了一个有希望的替代方案,克服了当前的临床限制.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
229
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
229
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
162
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
162
Inhaled Medications
280
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
280
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
Nitric Oxide Signaling Pathway
5.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.0K


